| scholarly article | Q13442814 |
| P2093 | author name string | Deniz Arslan | |
| Hasan Şenol Coşkun | |||
| Mükremin Uysal | |||
| Ali Murat Tatlı | |||
| Sema Sezgin Göksu | |||
| Burhan Savaş | |||
| Hakan Şat Bozcuk | |||
| Selda Cakal | |||
| Seyda Güenay Gündüz | |||
| P2860 | cites work | European cancer mortality predictions for the year 2011. | Q51506857 |
| Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. | Q53232788 | ||
| Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200 | Q56679480 | ||
| Global cancer statistics | Q22241238 | ||
| Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 | Q27860674 | ||
| The biology of VEGF and its receptors | Q27860704 | ||
| Estimates of cancer incidence and mortality in Europe in 2008. | Q34095813 | ||
| Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. | Q34590731 | ||
| First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study | Q35705210 | ||
| Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial | Q40343352 | ||
| OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-Go fashion in advanced colorectal cancer--a GERCOR study | Q46900220 | ||
| P433 | issue | 8 | |
| P921 | main subject | bevacizumab | Q413299 |
| capecitabine | Q420207 | ||
| P304 | page(s) | 2191-2196 | |
| P577 | publication date | 2014-08-15 | |
| P1433 | published in | International Journal of Clinical and Experimental Medicine | Q6051338 |
| P1476 | title | Treatment with capecitabine + bevacizumab following induction treatment with FOLFIRI + bevacizumab in metastatic colorectal carcinoma | |
| P478 | volume | 7 |
| Q28072433 | Molecular targeted therapy for the treatment of gastric cancer | cites work | P2860 |
Search more.